Clinical Trial Update: GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound [Phase 3]

View source ↗

Summary

Phase 3 trial assessing plaque regression with a PCSK9 antibody in hypercholesterolemia, measured by intravascular ultrasound; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: Amgen | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2018-01-04